Wellington Biomedical Innovation Master Investors (Cayman) I L.P. - 17 Nov 2022 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Reporting relationship: 10%+ Owner
Issuer ticker: ACRV
Reported as of: 17 Nov 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Nov 2022, 12:22:18 UTC
Prior SEC filing: 09 Nov 2022
Next SEC filing: 27 Mar 2024
Source filing: View source filing
Reporting owner signature: /s/ Wellington Biomedical Innovation Master Investors (Cayman) I L.P., By: Wellington Management Company LLP, as Investment Adviser, /s/ Peter McIsaac, Title: Authorized Person

Key filing fact

Wellington Biomedical Innovation Master Investors (Cayman) I L.P. filed Form 4 for Acrivon Therapeutics, Inc. (ACRV) on 21 Nov 2022.

Key facts

This page summarizes Wellington Biomedical Innovation Master Investors (Cayman) I L.P.'s Form 4 filing for Acrivon Therapeutics, Inc. (ACRV).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 21 Nov 2022, 12:22.

Change

Previous filing in this sequence was filed on 09 Nov 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ACRV transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +888,130
Change %
Price
Shares after: 888,130
Date: 17 Nov 2022
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACRV transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -2,190,131
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 17 Nov 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 888,130
Exercise price
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Wellington Biomedical Innovation Master Investors (Cayman) I L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

On November 17, 2022, the Series B Preferred Stock automatically converted into Common Stock on a 1-to-2.466 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series B Preferred Stock had no expiration date.